1. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
- Author
-
Wang HY, Cao ZX, Li LL, Jiang PD, Zhao YL, Luo SD, Yang L, Wei YQ, and Yang SY
- Subjects
- Algorithms, Heterocyclic Compounds chemistry, Inhibitory Concentration 50, Molecular Structure, Structure-Activity Relationship, Polo-Like Kinase 1, Cell Cycle Proteins antagonists & inhibitors, Drug Design, Drug Evaluation, Preclinical methods, Heterocyclic Compounds chemical synthesis, Heterocyclic Compounds pharmacology, Models, Molecular, Protein Serine-Threonine Kinases antagonists & inhibitors, Proto-Oncogene Proteins antagonists & inhibitors
- Abstract
Pharmacophore models of Polo-like kinase-1 (PLK1) inhibitors have been established by using the HipHop and HypoGen algorithms implemented in the Catalyst software package. The best quantitative pharmacophore model, Hypo1, which has the highest correlation coefficient (0.9895), consists of one hydrogen bond acceptor, one hydrogen bond donor, one hydrophobic feature, and one hydrophobic aliphatic feature. Hypo1 was further validated by test set and cross validation method. Then Hypo1 was used as a 3D query to screen several databases including Specs, NCI, Maybridge, and Chinese Nature Product Database (CNPD). The hit compounds were subsequently subjected to filtering by Lipinski's rule of five and docking study to refine the retrieved hits and as a result to reduce the rate of false positive. Finally, a total of 20 compounds were selected and have been shifted to in vitro and in vivo studies. As far as we know, this is the first report on the pharmacophore modeling even the first publicly reported virtual screening study of PLK1 inhibitors.
- Published
- 2008
- Full Text
- View/download PDF